Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris reports robust 2022 performance, eyes growth through strategic initiatives

Viatris showcased strong financial performance and strategic execution in 2022, with a focus on integration and debt reduction post-merger.
The company's emphasis on capital allocation, product launches, and market expansion highlights a balanced approach to growth and shareholder returns.
Challenges lie in effective debt management, successful product launches, and balancing R&D investments with capital returns for optimal growth.
Overall, Viatris remains poised for growth with opportunities in new product launches, market expansion, and revenue diversification in 2023.

Viatris reports robust Q1 earnings, eyes growth in key markets

Viatris delivered strong Q1 financial performance, reaffirmed 2023 guidance, and expressed confidence in strategic plan execution.
The company's focus on key therapeutic areas, successful acquisitions, and product developments position it for growth.
While facing challenges in base business erosion and market dynamics, Viatris is exploring opportunities in new products and strategic acquisitions for future growth.

Viatris reports robust Q2 earnings, eyes strategic divestitures for growth

Viatris (VTRS) had a strong Q2 2023, reaffirming guidance, showcasing revenue growth in key markets, and addressing analyst inquiries on tax structures and market impacts. The company's focus on strategic divestitures and therapeutic verticals presents growth opportunities amidst challenges in pricing and market dynamics.

Viatris reports robust Q3 results, navigates challenges for future growth

Viatris' Q3 performance reflects strong operational results, strategic divestitures, and a focus on shareholder value creation amidst challenges from FX and inflation.
The company's financial resilience, commitment to growth, and effective cost management underscore its ability to navigate market dynamics and drive long-term success.
With a solid foundation in place, Viatris remains well-positioned to capitalize on growth opportunities, drive innovation, and deliver value to shareholders.

Viatris reports strong 2023 performance and eyes transformational 2024

Viatris had a strong 2023 and anticipates a transformational 2024 with strategic investments and capital return to shareholders.
The company's collaboration with Idorsia for exclusive global rights to assets offers significant revenue growth potential and pipeline expansion.
Despite challenges like portfolio rationalization and FTC inquiry impact, Viatris is optimistic about future growth and product launches.

Viatris reports robust Q1 performance and charts growth opportunities

Viatris delivered strong financial performance, reaffirmed guidance, and introduced new revenue projections, showcasing stability and growth potential.
While facing divestiture challenges, the company's strategic initiatives, leadership additions, and pipeline progress position it for future success.
Opportunities for revenue growth, shareholder value enhancement, and innovation highlight Viatris' path towards sustained growth and market leadership.

Viatris excels in Q3 earnings, eyes growth through innovation

Viatris demonstrated strong financial performance in Q3 2024, showcasing revenue growth, debt repayment, and strategic investments. While facing challenges in Q4, the company remains committed to enhancing shareholder value and driving innovation. By leveraging its strengths and addressing key challenges, Viatris aims to seize growth opportunities and deliver long-term value to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biomarker data from CARE study characterizing cenerimod's mechanism of action in systemic lupus erythematosus also published in the Annals of the Rheumatic Diseases PITTSBURGH , Dec. 18, 2024 /PRNewswire/ --  Viatris Inc.  (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The results, published in Lancet Rheumatologyi , showed cenerimod 4 mg demonstrated clinically meaningful and sustained improvement from baseline on multiple measures of SLE disease activity compared to placebo, in addition to stable background SLE therapy.

Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology

Management to Participate in 7th Annual Evercore HealthCONx Conference Management to Participate in 7th Annual Evercore HealthCONx Conference

Mapi Pharma is Seeking New Depot Product Partnerships

Teva Pharmaceutical

Generic and biosimilar drugs are often preferred over the brand name version due to their cheaper prices. Generics are exact duplicates of the branded counterparts, while biosimilars are "similar" and often require clinical trials.

2 Generic Drug Stocks Ready to Surge in 2025

Britain's competition watchdog fined U.S. firm Viatris 1.5 million pounds ($1.88 million) on Friday for violating an order during its investigation into Theramex's acquisition of European rights to two of Viatris's women's healthcare product ranges.

UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe

Viatris Inc. (NASDAQ:VTRS ) Jefferies London Healthcare Conference Transcript November 21, 2024 5:30 AM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial Officer Corinne Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo All right. Good morning, everybody.

Viatris Inc. (VTRS) Management Presents at Jefferies London Healthcare Conference (Transcript)

Viatris Inc. (NASDAQ:VTRS ) UBS Global Healthcare Conference November 12, 2024 11:45 AM ET Company Participants Doretta Mistras - CFO Conference Call Participants Ashwani Verma - UBS Ashwani Verma Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma at UBS, and welcome to UBS Global Healthcare Conference with us.

Viatris Inc. (VTRS) UBS Global Healthcare Conference (Transcript)

Bargain Priced Viatris Reports Strong Q3 Earnings Results

Viatris Inc. VTRS reported third-quarter 2024 total net sales of $3.74 billion. That's down 5%, beating the consensus of $3.71 billion, but up about 3% on a divestiture-adjusted operational basis compared to third-quarter 2023 results.

Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown

VTRS Q3 earnings and sales beat estimates. New products perform well.

Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance

Viatris Inc. (NASDAQ:VTRS ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Corinne Le Goff - Chief Commercial Officer Conference Call Participants Glen Santangelo - Jefferies Jason Gerberry - Bank of America Ethan Brown - JPMorgan Ashwani Verma - UBS David Amsellem - Piper Sandler Balaji Prasad - Barclays Operator Good morning, everyone, and welcome to the Viatris Q3 2024 Earnings Call. All participants will be in a listen-only mode.

Viatris Inc. (VTRS) Q3 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Viatris (VTRS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Viatris (VTRS) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago.

Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.5% premarket.

Xanax maker Viatris beats quarterly estimates on demand for new generic drugs

PITTSBURGH , Nov. 7, 2024 /PRNewswire/ --  Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business[1]    Strong New Product Revenues of $133 Million Drove Growth Across Segments   U.S. GAAP Net Earnings were $95 Million; Adjusted EBITDA Grew ~4% to $1.3 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was $0.08 per Share; Adjusted EPS Grew ~6% to $0.75 per Share on a Divestiture-Adjusted Basis[2]    Repaid ~$1.9 Billion of Debt, Expects to Achieve its Long-Term Gross Leverage Target of ~3.0x by end of the Year[3]   Entered into Exclusive Licensing Agreement for Sotagliflozin, Expanding its Innovative Portfolio in Cardiovascular Diseases   Reaffirms 2024 Full-Year Outlook and Continues to Expect 2024 Full-Year Revenue Growth of ~2% on a Divestiture-Adjusted Operational Basis[4] Viatris Inc. (Nasdaq: VTRS) today announced robust financial results for the third quarter of 2024, driven by positive momentum against all three pillars of its strategy. The Company continued to demonstrate its ability to grow its base business, delivering total revenues of $3.8 billion including new product revenues of $133 million; it added to its financial strength with the repayment of approximately $1.9 billion of debt; and it expanded its innovative portfolio by entering into an exclusive licensing agreement with Lexicon Pharmaceuticals for sotagliflozin outside of the U.S. and Europe.

Viatris Reports Third Quarter Financial Results for 2024

Gilead Sciences

Moderna

Novo Nordisk

Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.

What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?

PITTSBURGH , Nov. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024, to shareholders of record as of the close of business on November 22, 2024.

Viatris Announces Third Quarter 2024 Dividend

Besides Wall Street's top -and-bottom-line estimates for Viatris (VTRS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics

PITTSBURGH , Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List. This award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider.

Viatris Named to Forbes' World's Top Companies for Women 2024 List

PITTSBURGH , Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the company will participate in two upcoming healthcare conferences. Details of the presentations can be found below: UBS Global Healthcare Conference Date: Tuesday, November 12, 2024 Time: 8:45 a.m.

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024.

Idorsia announces financial results for the first nine months of 2024

Viatris Inc. stock has experienced significant volatility since its 2020 inception, driven by disappointing early performance, asset sales, and fluctuating market expectations. Despite low P/E and P/S ratios suggesting a “screaming buy,” falling revenues and substantial debt challenge Viatris' growth prospects. CEO Scott Smith's “Phase 2” strategy focuses on new product launches and debt reduction, aiming to offset declining sales of older generics and established brands.

Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy

Lexicon Pharmaceuticals

Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH , Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets outside of the United States and Europe. Sotagliflozin was approved by the U.S. Food and Drug Administration in May 2023 to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

Treatment with once-daily EFFEXOR® met primary and all secondary efficacy endpoints in outpatient adults with GAD EFFEXOR® was generally well tolerated, consistent with its known safety profile Pharmaceuticals and Medical Devices Agency (PMDA) submission targeted for 2025 PITTSBURGH and TOKYO , Oct. 9, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced positive top-line results of its Phase 3 study (B2411367) in Japan evaluating the safety and efficacy of EFFEXOR® (venlafaxine) in adults with generalized anxiety disorder (GAD). The study achieved its primary objective of superiority of anxiolytic effects of venlafaxine compared to placebo at 8 weeks, based on the change in the Hamilton Anxiety Rating Scale (HAM-A) total score from baseline (two-sided p-value=0.012).

Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)

PITTSBURGH , Oct. 8, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2024. This is the fourth year in a row that Viatris has received this recognition, which is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider.

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row

PITTSBURGH , Sept. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah Acquisition Sub Inc. ("UAS") for up to an increased maximum aggregate principal amount of $575,003,000 of its outstanding 3.950% Senior Notes due 2026 (the "Maximum Tender Offer Notes") validly tendered and not validly withdrawn at or prior to the Early Tender Date (as defined below) (such increased maximum aggregate principal amount, the "Maximum Tender Cap").

News for Viatris Stock (VTRS)